The global male infertility market size is expected to reach USD 5.9 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.9% from 2022 to 2030. Advancements in diagnostic tests and increasing infertility in males are some of the major factors driving the market for male infertility. In addition, lifestyle-associated diseases causing infertility, rising obesity, and the growing aging population are likely to boost the market growth during the forecast period. In the U.S., one-third of infertility cases are due to female factors, one-third due to male factors, and the remaining one-third of the cases are unknown.
The COVID-19 pandemic had a severe impact on healthcare services. The diagnostic kits and critical medical supplies witnessed growing demand. On the other hand, most elective medical procedures dropped by around 50%. As only emergency medical procedures were allowed during the initial phase of the pandemic, the market observed a decline.
DNA fragmentation technique emerged as the largest test segment in 2021 and is expected to maintain its lead during the forecast period. Increasing adoption in developed countries and high cost due to higher sensitivity and reliable analysis of sperm DNA integrity are the key factors driving the segment. The Assisted Reproductive Technology (ART) and varicocele surgery segment dominated the market for male infertility in 2021 due to its high success rate. Intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) are the most commonly used ARTs.
Partnerships and agreements among key manufacturers are expected to boost the market growth in the coming years. For instance, in July 2019, Vitrolife entered into a collaboration with Prime Tech for the development and exclusive marketing of the Piezo technique for improved Intracytoplasmic Sperm Injection (ICSI) procedure in human IVF globally except Malaysia, Thailand, and Japan. Additionally, Vitrolife will initiate the regulatory approval procedures in various markets for the future commercialization of the technology.
Request a free sample copy or view report summary: Male Infertility Market Report
Based on test, DNA fragmentation technique dominated the market in 2021 and is estimated to witness significant growth over the forecast period due to the higher accuracy of the test
The oxidative stress analysis test segment is gaining popularity due to the accurate determination of reactive oxygen species. In March 2018, Aytu BioScience, Inc. received registration from COFEPRIS in Mexico for MiOXSYS System, which is used for diagnosing male infertility
Europe dominated the market in 2021 and is expected to maintain its lead during the forecast period due to high adoption of costlier treatment, strong diagnosis rate, and increased awareness
Asia Pacific is projected to witness substantial growth over the forecast period owing to increasing investment by several clinics and pharmaceutical companies and growing healthcare expenditure
Grand View Research has segmented the global male infertility market based on test, treatment, and region:
Male Infertility Test Outlook (Revenue, USD Million, 2017 - 2030)
DNA Fragmentation Technique
Oxidative Stress Analysis
Computer Assisted Semen Analysis
Sperm Penetration Assay
Male Infertility Treatment Outlook (Revenue, USD Million, 2017 - 2030)
Assisted Reproductive Technology and Varicocele Surgery
Male Infertility Regional Outlook (Revenue, USD Million, 2017 - 2030)
Middle East & Africa
List of Key Players of Male Infertility Market
Aytu BioScience, Inc.
Cadila Healthcare Ltd.
Halotech DNA SL
EMD Sereno, Inc.
SCSA Diagnostics, Inc.
Intas Pharmaceuticals Ltd.
This report has a service guarantee. We stand by our report quality.
Your transaction & personal information is safe and secure.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
Avail customized purchase options to meet your research needs:
"The quality of research they have done for us has been excellent..."